This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Egberts, J.-H. Articles by Trauzold, A. PubMed PubMed Citation Articles by Egberts, J.-H. Articles by Trauzold, A.

Anti–Tumor Necrosis Factor Therapy Inhibits Pancreatic Tumor Growth and Metastasis

¹ Division of Molecular Oncology, Department of General Surgery and Thoracic Surgery; ² Institute of Immunology; and ³ Department of Nuclear Medicine, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany; and ⁴ Department of Molecular Internal Medicine, Medical Clinic and Polyclinic II, University of Würzburg, Würzburg, Germany

Requests for reprints: Holger Kalthoff, Division of Molecular Oncology, Department of General Surgery and Thoracic Surgery, University Hospital of Schleswig-Holstein, Campus Kiel, Arnold-Heller-Strasse 7, 24105 Kiel, Germany. Phone: 49-431-5971938; Fax: 49-431-5971939; E-mail: hkalthoff{at}email.uni-kiel.de and Harald Wajant, Department of Molecular Internal Medicine, Medical Clinic and Polyclinic II, University of Würzburg, Röntgenring 11, 97070 Würzburg, Germany. Phone: 49-931-20171010; Fax: 49-931-20171070; E-mail: harald.wajant{at}mail.uni-wuerzburg.de.

Key Words: pancreatic cancer • therapy • TNF • etanercept • infliximab

Chronic inflammation has been implicated in the pathogenesis of many severe autoimmune disorders, as well as in diabetes, pulmonary diseases, and cancer. Inflammation accompanies most solid cancers including pancreatic ductal adenocarcinoma (PDAC), one of the most fatal cancers with surgery being the only curative therapeutic approach currently available. In the present work, we investigated the role of the major proinflammatory cytokine tumor necrosis factor (TNF) in the malignancy of PDAC cells in vitro and in vivo. In vitro, TNF strongly increased invasiveness of Colo357, BxPc3, and PancTuI cells and showed only moderate antiproliferative effect. TNF treatment of mice bearing orthotopically growing PDAC tumors led to dramatically enhanced tumor growth and metastasis. Notably, we found that PDAC cells themselves secrete TNF. Although inhibition of TNF with infliximab or etanercept only marginally affected proliferation and invasiveness of PDAC cells in vitro, both reagents exerted strong antitumoral effects in vivo. In severe combined immunodeficient mice with orthotopically growing Colo357, BxPc3, or PancTuI tumors, human-specific anti-TNF antibody infliximab reduced tumor growth and metastasis by about 30% and 50%, respectively. Importantly, in a PDAC resection model performed with PancTuI cells, we found an even stronger therapeutic effect for both anti-TNF compounds. Infliximab and etanercept reduced the number of liver metastases by 69% and 42%, respectively, as well as volumes of recurrent tumors by 73% and 51%. Thus, tumor cell–derived TNF plays a profound role in malignancy of PDAC, and inhibition of TNF represents a promising therapeutic option particularly in adjuvant therapy after subtotal pancreatectomy. [Cancer Res 2008;68(5):1443–50]